Utilization of metabolic, transport and receptor-mediated processes to deliver agents for cancer diagnosis

Advanced Drug Delivery Reviews

Volumn 37, Issue 1-3, 1999, Pages 189-211

  Cutler, Cathy S ^a   Lewis, Jason S ^a   Anderson, Carolyn J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Diagnosis; Imaging; PET; Radiopharmaceuticals; SPECT; Tumor

Indexed keywords

AGENTS; BIOLOGICAL MEMBRANES; COMPUTERIZED TOMOGRAPHY; METABOLISM; NUCLEAR MEDICINE; ONCOLOGY; OXYGEN; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPES; THALLIUM; TRANSPORT PROPERTIES;

CANCER DIAGNOSIS; RADIOPHARMACEUTICALS; RECEPTOR MEDIATED PROCESS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TUMOR;

CONTROLLED DRUG DELIVERY;

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 131; AMINO ACID; COPPER COMPLEX; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; GALLIUM CITRATE GA 67; MEDRONATE TECHNETIUM TC 99M; OXIDRONATE TECHNETIUM TC 99M; OXYGEN 15; RADIOPHARMACEUTICAL AGENT; RECEPTOR; SOMATOSTATIN DERIVATIVE; STEROID RECEPTOR; THALLIUM 201; THIOSEMICARBAZONE DERIVATIVE;

BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSPORT; GAMMA SCINTIGRAPHY; HUMAN; HYPOXIA; MEMBRANE TRANSPORT; MULTIDRUG RESISTANCE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TECHNIQUE;

EID: 0344958762     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00093-3     Document Type: Review

References (192)

1. G. Subramanian, B.A. Rodes, J.F. Cooper, V.D. Sodd, Radiopharmaceuticals, The Society of Nuclear Medicine, New York, 1975.
2. B.A. Rhodes, B.Y. Craft, Basics of Pharmacy, C.V. Mosby Co., St. Louis, MO, 1978.
3. R.J. Callahan, F.P. Castronovo, Development of technetium-99m labeled 1-hydroxy-ethylidene-1,1-disodium phosphonate for skeletal imaging, Am. J. Hosp. Pharm. 30 (1973) 614-617.
4. Y. Yano, J. McRae, D.C. Van Dyke, H.O. Anger, Technetium-99m-labeled stannous ethane-1-hydroxy-11-diphosphonate: a new bone scanning agent, J. Nucl. Med. 14 (1973) 73-78.
5. J.W. Keyes, J. Carey, D. Moses, W. Beierwaites, Manual of Nuclear Medicine Procedures, CRC Press, Cleveland, Ohio, 1973.
6. N.D. Heindel, H.D. Bums, T. Honda, L.W. Brady, The Chemistry of Radiopharmaceuticals, Masson, New York, 1978.
7. R.P. Beaney, Positron emission tomography in the study of human tumors, Sem. Nucl. Med. 14 (1984) 324-341.
8. A.A. Lammertsmaa, T. Jones, Low oxygen extraction fraction in tumors measured with the oxygen-15 steady state technique: effect of tissue heterogeneity, Br. J. Radiol. 65 (1992) 697-700.
9. K. Mineura, T. Sasajima, M. Kowada, T. Ogawa, J. Hatazawa, K. Uemura, Long-term positron emission tomography evaluation of slowly progressive gliomas, Eur. J. Cancer 32A (1996) 1257-1260.
10. 15O, J. Nucl. Med. 24 (1983) 782-789.
11. A. Dimitrakopoulou, L.G. Strauss, J.H. Clorius, H. Ostertag, P. Schlag, M. Heim, F. Oberdorfer, F. Helus, U. Haberkom, G. van Kaick, Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma, J. Nucl. Med. 34 (1993) 1075-1081.
12. A. Dimitrakopoulou-Strauss, L.G. Strauss, P. Schlag, P. Hohenberger, G. Imgartinger, F. Oberkorfer, J. Doll, G. van Kaick, Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma, J. Nucl. Med. 39 (1998) 465-473.
13. T. Nariai, M. Senda, K. Ishii, T. Maehara, S. Wakabayashi, H. Toyama, K. Ishiwata, K. Hirakawa, Three-dimensional imaging of cortical structure, function and glioma for tumor resection, J. Nucl. Med. 38 (1997) 1563-1568.
14. H.G. Petering, H.H. Buskirk, G.E. Underwood, Antitumor action of 2-oxo-3-ethyoxybutyraldehyde bis(thiosemicarbazone) and similar compounds, Cancer Res. 24 (1964) 367-372.
15. D.H. Petering, Physiochemical properties of the anti-tumor agent 3-ethyoxo-2-oxobutyraldehyde bis-(thiosemicarbazonato)-copper(II), Bioinorg. Chem. 1 (1972) 255-271.
16. D.H. Petering, The reaction of 3-Ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato)copper(II) with thiols, Bioinorg. Chem. 1 (1972) 273-288.
17. 62Cu-PTSM) in the murine brain; a novel radiopharmaceutical for brain positron emission tomography (PET) imaging, Biol. Pharm. Bull. 16 (1993) 146-149.
18. 4-methylthiosemicarbazonato)copper(II): Synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial pefusion, J. Nucl. Med. 31 (1990) 1989-1996.
19. J.L. Lacy, S.C. Chien, J.K. Lim, C.J. Mathias, M.A. Green, Modular automated Zn-62/Cu-62 PET radiopharmaceutical generator, J. Nucl. Med. 36 (1995) 49.
20. 62Cu-PTSM, Nucl. Med. Biol. 19 (1992) 39-44.
21. D.W. McCarthy, R.E. Shefer, R.E. Klinkowstein, L.A. Bass, W.H. Margeneau, C.S. Cutler, C.J. Anderson, M.J. Welch, Efficient production of high specific activity Cu using a biomedical cyclotron, Nucl. Med. Biol. 24 (1997) 35-43.
22. L.A. Bass, D.W. McCarthy, L.A. Jones, P.D. Cutler, R.E. Shefer, R.E. Klinkowstein, S.W. Schwarz, C.S. Cutler, J.S. Lewis, C.J. Anderson, M.J. Welch, High purity production and potential applications of copper-60 and copper-61, J. Label Comp. Radiopharm. 40 (1997) 325-327.
23. P.J. Blower, J.S. Lewis, J. Zweit, Copper radionuclides and radiopharmaceuticals in nuclear medicine, Nucl. Med Biol. 23 (1996) 957-980.
24. 4-methylthiosemicarbazone), Nucl. Med. Biol. 14 (1987) 59-61.
25. E.K. John, M.A. Green, Structure-activity relationships for metal-labeled blood flow tracers: comparison of ketoaldehyde bis(thiosemicarbazonato)copper(II) derivatives, J. Med. Chem. 33 (1990) 1764-1770.
26. M.E. Shelton, M.A. Green, C.J. Mathias, M.J. Welch, S.R. Bergmann, Assessment of regional myocardial and renal blood flow using copper-PTSM and positron emission tomography, Circulation 82 (1990) 990-997.
27. C.J. Mathias, M.J. Welch, D.J. Perry, A.H. McGuire, X. Zhu, J.M. Connett, M.A. Green, Investigation of copper-PTSM as a PET tracer for tumor blood flow, Nucl. Med. Biol. 18 (1991) 807-811.
28. J.L. Ritchie, G.W. Hamilton, Thallium-201 myocardial imaging, in: J.L. Ritchie, G.W. Hamilton, F.G. Wackers (Eds.), Biological Properties of Thallium, Raven Press, New York, 1978.
29. P.J. Gehring, P.B. Hammond, The interrelationship between thallium and potassium in animals, J. Pharmacol. Exp. Ther. 55 (1967) 187-201.
30. A.M. Sehweil, J.H. McKillop, R. Milroy, R. Wilson, H.M. Abdel-Dayem, Y.T. Omar, Mechanism of thallium-201 uptake in tumors, Eur. J. Nucl. Med. 15 (1989) 376-379.
31. A.D. Waxman, L. Ramana, J. Said, Thallium scintigraphy in lymphoma: relationship to gallium-67 (abstract), J. Nucl. Med. 30(S) (1989) 915.
32. +-2Cl-cotransport is the central mechanism of ion uptake, Nuklearmedizin 25 (1986) 24-27.
33. H.S. Winchell, Mechanisms for localization of radiopharmaceuticals in neoplasms, Sem. Nucl. Med. 6 (1976) 371-378.
34. T. Brismar, V.P. Collins, M. Kesselberg, Thallium-201 uptake relates to membrane potential and potassium premeability in human glioma cells, Brain Res. 500 (1989) 30-36.
35. K.T. Black, R.A. Hawkins, K.T. Kim, Thallium-201 (SPECT): A quantitative technique to distinquish low grade from malignant brain tumors, J. Neurosurgery 71 (1989) 342-346.
36. K.T. Kim, K.L. Black, D. Marciano, J.C. Mazziota, B.H. Guze, S. Grafton, R.A. Hawkins, D.P. Becker, Thallium-201 SPECT imaging of brain tumors: methods and results, J. Nucl. Med. 31 (1990) 965-969.
37. H. Macapinlac, C.I. Caluser, J. Finlay et al, Correlation of Tl-201 brain SPECT with MR imaging in the post therapy evaluation of patients with primary malignant brain tumors, Radiology 181 (1991) 129.
38. H. Macapinlac, J. Finlay, C. Caluser, S. Yeh, A. Scott, R. Delapaz, K. Lindsley, R. Finn, A. Muraki, S. Larson, H. Abdel-Dayem, Comparison of Tl-201 SPECT and F-18 FDG PET imaging with MRI (Gd-DTPA) in the evaluation of recurrent and supratentorial and infratentorial brain tumors, J. Nucl. Med. 33 (1992) 862.
39. V.W. Lee, AIDS Related Kaposi Sarcoma, AJR Am. J. Roentgenol. (1988) 1233-1235.
40. M. Lorberboym, F. Wallach, L. Estok, R.E. Mosesson, M. Sacher, C.K. Kim, J. Machac, Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and non-malignant lesions in AIDS patients, J. Nucl. Med. 39 (1997) 1366-1369.
41. L. Ramanna, A. Waxman, G. Binney, S. Waxman, J. Mirra, G. Rosen, Thallium-201 scintigraphy in bone sarcoma: comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response, J. Nucl. Med. 31 (1990) 567-572.
42. P.M. Mauch, Principles of Oncology, Harper and Row, New York, 1983.
43. American Cancer Society Cancer Statistics 1991, Cancer J. Clin. 37 (1991).
44. I. Fogelman, Bone Scanning in Clinical Practice, Springer-Verlag, New York, 1987.
45. H.M. Chilton, R.L. Witcofski, Pharmaceuticals in Medical Imaging, Macmillan Publishing Co., New York, 1990.
46. S.S. Jurrison, J.J. Benedict, B.C. Elder, R. Whittle, E. Deutsch, Inorg. Chem. 22 (1983) 1332.
47. C.L. De Ligny, W.J. Gelsema, T.G. Tji, Y.M. Huigen, H.A. Vink, Bone seeking radiopharmaceuticals, Nucl. Med. Biol. 17 (1990) 161-179.
48. T.C. Pinkerton, W.R. Heinenian, E. Deutsch, Separation of technetium hydroxyethylidene diphosphonate complexes by anion exchange high-performance liquid chromatography, Anal. Chem. 52 (1980) 1106.
49. G.M. Wilson, T.C. Pinkerton, Anal. Chem. 57 (1985) 246.
50. Z.H. Oster, P. Som, S.C. Srivastava, R.G. Fairchild, G.E. Meinken, G.Y. Tillman, D.F. Sacker, P. Richards, H.L. Atkins, A.B. Brill, F.F. Knapp, T.A. Butler, The development and in vivo behavior of Sn containing radiopharmaceuticals. II. Autoradiographic and scintigraphic studies in normal animals and in animal models of bone disease, Int. J. Nucl. Med. Biol. 12 (1985) 175-184.
51. J. Ohiron, W.A. Volkert, J. Garlich, R.A. Holmes, Determination of lesion to normal bone uptake ratios of skeletal radiopharmaceuticals by QARG, Nucl. Med. Biol. 18 (1991) 235-240.
52. L. Rosenthal, J. Stern, A.A. Arzoumanian, A clinical comparison of MDP and DMAD. Clin. Nucl. Med. 7 (1982) 403-406.
53. M.L. Smith, W. Martin, J.H. McKillop, I. Fogelman, Improved lesion detection with dimethyl-amino-diphosphonate: A report of two cases, Eur. J. Nucl. Med. 9 (1984) 519-520.
54. P. Rigo, P. Paulus, B.J. Kaschten, R. Hustinx, T. Bury, G. Jerusalem, T. Benoit, J. Foidart-Willems, Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose, Eur. J. Nucl. Med. 23 (1996) 1641-1674.
55. T.A. Smith, FDG uptake, tumour characteristics and response to therapy: a review, Nucl. Med. Commun. 19 (1998) 97-105.
56. R.L. Wahi, R.L. Cody, G.D. Hutchins, E.E. Mudgett, Primary and metastatic breast carcinoma: initial clinical evaluation with PET and the radiolabeled glucose analog 2-[F-18]-fluoro-deoxy-2-D-glucose (FDG), Radiology 179 (1991) 3920-3925.
57. O.E. Nieweg, E.E. Kim, W.-H. Wong, W.F. Broussard, S.E. Singletary, G.N. Hortobagyi, R.S. Tilbury, Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer, Cancer 71 (1993) 3920-3925.
58. P. Lindholm, H. Minn, S. Leskinen-Kallio, J. Bergman, U. Ruotsalainen, H. Joensuu, Influence of the blood glucose concentration on FDG uptake in cancer - a PET study, J. Nucl. Med. 34 (1993) 1-6.
59. R.A. Hawkins, M.E. Phelps, S.C. Huang, Effects of temporal sampling, glucose metabolic rats and disruptions of the blood-brain barrier on the FDG model with and without a vascular compartment: studies in human brain tumors with PET, J. Cerebral Blood Flow Metab. 6 (1986) 170-183.
60. 18F]fluorodeoxyglucose in brain tumors, a powerful diagnostic and prognostic tool, Invest. Radiology 22 (1987) 360-371.
61. 18F]fluorotyrosine in tumor bearing mice, Nucl. Med. Biol. 20 (1993) 895-899.
62. 18F]FDG in brain abscess: a PET study, J. Comp. Assis. Tomography 14 (1990) 486-487.
63. R. Kubota, S. Yamada, K. Kubota, K. Ishiwata, N. Tamahashi, T. Ido, Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography, J. Nucl. Med. 33 (1992) 1972-1980.
64. R.L. Wahl, S.J. Fisher, A comparison of FDG, L-methionine and thymidine accumulation into experimental injections and reactive lymph nodes, J. Nucl. Med. 34 (1991) 104.
65. W. Vaalburg, H.H. Coenen, C. Crouzel, P.H. Elsinga, B. Langstrom, C. Lemaire, G.J. Meyer, Amino acids for the measurement of protein synthesis in vivo by PET, Nucl. Med. Biol. 19 (1992) 227-237.
66. 11C]methionine for measuring in vivo protein synthesis rats with PET, J. Nucl. Med. 29 (1988) 1419-1427.
67. K. Ishiwata, K. Kubota, M. Miurakami, R. Kubota, T. Sasaki, S. Ishii, M. Senda, Reevaluation of amino acid PET studies: can the protein synthesis rats in brain and tumor tissues be measured in vivo? J. Nucl. Med. 34 (1993) 1936-1943.
68. R. Huovinen, S. Leskinen-Kallio, K. Nagren, P. Lehikoinen, U. Ruotsalainen, M. Teras, Carbon-11-methionine and PET in evaluation of treatment response of breast cancer, Br. J. Cancer 67 (1993) 787-791.
69. 11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET, J. Nucl. Med. 38 (1997) 517-522.
70. A.M.J. Paans, J. Pruim, A. van Waarde, A.T.M. Willemsen, W. Vaalburg, Radiolabelled tyrosine for the measurement of protein synthesis rate in vivo by positron emission tomography, Bailliere's Clin. Endocrin. Metab. 10 (1996) 497-510.
71. J.A. Katzenellenbogen, R.E. Coleman, R.A. Hawkins, K.A. Krohn, S.M. Larson, J. Mendelsohn, C.K. Osborne, D. Piwnica-Worms, R.C. Reba, B.A. Siegel, M.J. Welch, F. Shtern, Tumor receptor imaging: Proceedings of the National Cancer Institute Workshop, Review of Current Work, and Prospective for Further Investigations, Clin. Cancer Res. 1 (1995) 921-932.
72. 67Ga citrate, J. Nucl. Med. 10 (1969) 103-105.
73. S.W. Gunesekera, L.J. King, P.J. Lavender, The behavior of tracer gallium-67 towards serum proteins, Clin. Chim. Acta 39 (1972) 401-406.
74. 67Ga localization in malignant disease, Nucl. Med. Biol. 23 (1996) 745-751.
75. C.A. Luttropp, J.A. Jackson, B.J. Jones, M.-H. Sohn, R.E. Lynch, K.A. Morton, Uptake of gallium-67 in transfected cells and tumors absent or enriched in the transferrin receptor, J. Nucl. Med. 39 (1998) 1405-1411.
76. M.A. Mintun, D.R. Dennis, M.J. Welch, C.J. Mathias, D.P. Schuster, Measurements of pulmonary vascular permeability with PET and gallium-68 transferrin, J. Nucl. Med. 28 (1987) 1704-1716.
77. 131I]Iodobenzylguanidine, J. Nucl. Med. 21 (1980) 349-353.
78. H. Sinzinger, F. Renner, S. Granegger, Unsuccessful iodine-131 MIBG imaging of carcinoid tumors and apudonias (letter), J. Nucl. Med. 27 (1986) 1221-1222.
79. J. Bomanji, J.L. Hungerford, J.E. Kingston, D.A. Levison, K.E. Brittin, I metaiodobenzylguanidine (MIBG) scintigraphy of retinoblastoma: preliminary experience, Br. J. Ophthamol. 73 (1989) 146-150.
80. 131I-metaiodobenzylquanidine (MIBG) for bronchial oat cell cancer and melanoma detection, Eur. J. Nucl. Med. 15 (1989) 629-631.
81. N.A. Petry, B. Shapiro, Pharmaceuticals in Medical Imaging, Macmillan Publishing Co., New York, 1990.
82. J.V. Glowniak, J.E. Kilty, S.G. Amara, B.J. Hoffman, F.E. Turner, Evaluation of metaiodobenzylquanidine uptake by the norepinephrine, dopamine and serotonin transporters, J. Nucl. Med. 34 (1993) 1140-1146.
83. S. Jacques Jr., M.C. Tobes, J.C. Sisson, J.A. Baker, D.M. Wieland, Comparison of the sodium-dependency of uptake of meta-iodobenzylguanidine and norepinephrmne into cultured bovine adrenomedullary cells, Mol. Pharmacol. 26 (1984) 539-546.
84. M.C. Tobes, S. Jacques Jr., D.M. Wieland, J.C. Sisson, Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylquanidine, J. Nucl. Med. 26 (1985) 897-907.
85. L. Von Moll, A.J. McEwan, B. Shapiro, J.C. Sisson, M.D. Gross, R. Lloyd, E. Beals, W.H. Beierwaltes, N.W. Thompson, Iodine-131-MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma, J. Nucl. Med. 28 (1987) 979-988.
86. B. Gasnier, M.P. Roisen, D. Scherman, S. Coornaert, G. Desplanones, J.P. Henry, Uptake of metaiodobenzylguanidine by bovine chromaffin granule membranes, Mol. Pharmacol. 29 (1985) 275-280.
87. S.D.J. Yeh, L. Helson, R.S. Benau, Correlation between iodine-131 MIBG imaging and biologic markers in advanced neuroblastoma, Clin. Nucl. Med. 13 (1988) 46-52.
88. B. De Bernardi, D. Rogers, M. Carli, E. Madon, T. de Laurentis, S. Bagnulo, M.T. di Tullio, G. Paolucci, G. Pastore, Localized neuroblastoma: surgical and pathologic staging, Cancer 60 (1987) 1066-1072.
89. R. Nitschke, E.I. Smith, S. Shochat, G. Altshuler, H. Travers, J.J. Shuster, Localized neuroblastoma treated by surgery: a pediatric oncology group study, J. Clin. Oncol. 6 (1988) 1271-1279.
90. G.M. Haase, K.Y. Wong, A.A. de Lorimier, H.N. Sather, G.D. Hammond, Improvement in survival after excision of primary tumor in stage III neuroblastoma, J. Pediatr. Surg. 24 (1989) 194-200.
91. K.K. Matthay, D. Stram, R.C. Seeger, J. Atkinson, H. Shimada, G.D. Hammond, A prospective childrens cancer group study of stage II neuroblastoma treated with surgery alone, Proc. Am. Soc. Clin. Oncol. 12 (1993) 414.
92. S. Tsuchimochi, M. Nakajo, Y. Nakabeppu, A. Tani, Metastatic pulmonary pheochromocytomas: positive I-123 MIBG SPECT with negative I-131 MIBG and equivocal I-123 MIBG planar imaging, Clin. Nucl. Med. 22 (1997) 687-690.
93. R. Guillemin, Peptides in the brain: the new endocrinology of the neuron, Science 202 (1978) 390-402.
94. S. Reichlin, Somatostatin (part 1), New Engl. J. Med. 309 (1983) 1495-1501.
95. S. Reichlin, Somatostatin (part 2), New Engl. J. Med. 309 (1983) 1556-1563.
96. J.C. Reubi, L.K. Kvols, E.P. Krenning, S.W.J. Lamberts, Distribution of somatostatin receptors in normal and tumor tissue, Metabolism 39(2) (1990) 78-81.
97. W. Bauer, U. Briner, W. Doepfner, R. Haller, R. Huguenin, P. Marbach, T.J. Petcher, J. Pless, SMS 201-995, Life Sci. 31 (1982) 1133-1140.
98. W.H. Bakker, R. Albert, C. Bruns, W.A.P. Breeman, L.J. Hofland, P. Marbach, J. Pless, D. Pralet, B. Stolz, J.W. Koper, S.W.J. Lamberts, T.J. Visser, E.P. Krenning, [111In-DTPA-D-Phe]-Octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation, Life Sci. 49 (1991) 1583-1591.
99. W.H. Bakker, E.P. Krenning, J.C. Reubi, W.A.P. Breeman, B. Setyono-Han, M. de Jong, P.P.M. Kooij, C. Bruns, P.M. van Hagen, P. Marbach, T.J. Visser, J. Pless, S.W.J. Lamberts, In vivo application of [In-111-DTPA-D-Phe]-Octreotide for detection of somatostatin receptor-positive tumors in rats, Life Sci. 49 (1991) 1593-1601.
100. E.P. Krenning, W.H. Bakker, P.P.M. Kooij, W.A.P. Breeman, H.Y. Oei, M. de Jong, J.C. Reubi, T.J. Visser, C. Bruns, D.J. Kwekkeboom, A.E.M. Reijs, P.M. van Hagen, J.W. Koper, S.W.J. Lamberts, Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-Octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-Octreotide, J. Nucl. Med. 23 (1992) 652-658.
101. 3]-octreotide: the rotterdam experience with more than 1000 patients, Eur. J. Nucl. Med. 20 (1993) 716-731.
102. C.J. Anderson, T.S. Pajeau, W.B. Edwards, E.L.C. Sherman, B.E. Rogers, M.J. Welch, In vitro and in vivo evaluation of copper-64-labeled octreotide conjugates, J. Nucl. Med. 36 (1995) 2315-2325.
103. P.M. Smith-Jones, B. Stolz, C. Bruns, R. Albert, H.W. Reist, R. Fridrich, H.R. Mäcke, Gallium-67/gallium-68-[DFO]-octreotide - a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies, J. Nucl. Med. 35 (1994) 317-325.
104. 68Ga] labelled DFO-octreotide (SDZ-216-927) for PET studies of somatostatin receptor positive tumors, Horm. Metab. Res. 26 (1994) 452-459.
105. 86Y-DTPA-octreotide, Nucl. Med. Biol. 24 (1997) 275-286.
106. F. Dehdashti, C.J. Anderson, D.D. Trask, L.A. Bass, S.W. Schwarz, P.D. Cutler, D.W. McCarthy, M.V. Lanahan, Initial results with PET imaging using Cu-64-labeled TETA-Octreotide in patients with carcinoid tumor (abstract), J. Nucl. Med. 38 (1997) 103.
107. P.M. Smith-Jones, B. Stolz, R. Albert, G. Ruser, H. Mäcke, U. Briner, L. Tolsvai, G. Weckbecker, C. Bruns, Synthesis, radiolabelling, and evaluation of DTPA/octreotide conjugates for radiotherapy, J. Label Comp. Radiopharm. 37 (1995) 499-501.
108. 3]octreotide, a promising somatostatin analogue for radionuclide therapy, Eur. J. Nucl. Med. 24 (1997) 368-371.
109. 3-octreotide as measured in baboons by means of yttrium-86 and PET, J. Nucl. Med. 38 (1997) 60.
110. B. Stolz, P. Smith-Jones, R. Albert, L. Tolcsvai, U. Briner, G. Ruser, H. Mäcke, G. Weckbecker, C. Bruns, Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer, Digestion 57(1) (1996) 17-21.
111. D.A. Pearson, J. Lister-James, W.J. McBride, D.M. Wilson, L.J. Martel, E.R. Civitello, J.E. Taylor, B.R. Moyer, R.T. Dean, Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies, J. Med. Chem. 39 (1996) 1361-1371.
112. S. Vallabhajosula, B.R. Moyer, J. Lister-James, B.J. McBride, H. Lipszyc, H. Lee, D. Bastidas, R.T. Dean, Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides, J. Nucl. Med. 37 (1996) 1016-1022.
113. C.J. Palestro, R. Bitton, M.B. Tomas, D. Myssiorek, K.K. Bhargava, Y.M. Baran, P829: A technetium-labeled peptide for imaging tumors possessing somatostatin receptors, J. Nucl. Med. 38 (1997) 236.
114. 3]Octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy, Int. J. Cancer 75 (1998) 406-411.
115. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy, Cancer Res. 58 (1998) 437-441.
116. 3-Octreotate: somatostatin receptor binding studies, rodent biodistribution and primate PET imaging, J. Nucl. Med. 39 (1998) 63.
117. J.A. Katzenellenbogen, Designing steroid receptor-based radiotracers to image breast and prostate cancer, J. Nucl. Med. 36(S) (1995) 8-13.
118. 77Br]-16α-bromoestradiol-17β: a high specific-activity gamma-emitting tracer with uptake in rat uterus and induced mammary tumors, J. Nucl. Med. 22 (1981) 42-47.
119. P.C. Pieslor, R.E. Gibson, W.C. Eckelman, K.K. Oates, B. Cook, R.C. Reba, Three radioligands compared for determining cytoplasmic estrogen-receptor content of human breast carcinomas, Clin. Chem. 28 (1982) 532-537.
120. 125I]-iodoestradiol-17β, J. Nucl. Med. 23 (1982) 420-424.
121. 125I]-iodovinyl-11β-methoxyestradiol as a highly selective radioligand for tissues containing estrogen receptors: concise communication, J. Nucl. Med. 25 (1984) 998-1002.
122. D.O. Kiesewetter, M.R. Kilbourn, S.W. Landvatter, D.F. Heiman, J.A. Katzenellenbogen, M.J. Welch, Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats, J. Nucl. Med. 25 (1984) 1212-1221.
123. 18F]fluoromoxestrol: a potent metabolically stable Positron Emission Tomography imaging agent for estrogen receptor positive human breast tumors, Life Sci. 53 (1993) 811-819.
124. 18F]Fluoro-17β-estradiol uptake in metastatic breast carcinoma, J. Nucl. Med. 32 (1991) 1526-1531.
125. C.M. Mendel, The free hormone hypothesis: a physiologically based mathematical model, Endocrine Rev. 10 (1989) 232-274.
126. D.J. Hyrb, M.S. Khan, N.A. Romas, W. Rosner, The control of the interaction of sex hormone-binding globulin with its receptor by steroid hormones, J. Biol. Chem. 265 (1990) 6048-6054.
127. S.D. Jonson, M.J. Welch, PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins, Quart. J. Nucl. Med. 42 (1998) 8-17.
128. A. Liu, J.A. Katzenellenbogen, H.F. VanBrocklin, C.J. Mathias, M.J. Welch, 20-[18F]fluoromibolerone, a positron-emitting radiotracer for androgen receptors: synthesis and tissue distribution studies, J. Nucl. Med. 32 (1991) 81-88.
129. 3) amine phenol ligands, Inorg. Chem. 31 (1992) 5400-5407.
130. T.A. Bonasera, J.P. O'Neil, M. Xu, J.A. Dobkin, P.D. Cutler, L.L. Lich, Y.S. Choe, J.A. Katzenellenbogen, M.J. Welch, Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons, J. Nucl. Med. 37 (1996) 1009-1015.
131. P.D. Cutler, F. Dehdashti, B.A. Siegel, J.B. Downer, M.J. Welch, Investigation of a prostate ligand 16β-[F-18]Fluoro-5α-dihydrotestosterone for staging of prostate carcinoma, J. Nucl. Med. 37 (1996) 87.
132. F. Dehdashti, J.E. Mortimer, B.A. Siegel, L.K. Griffeth, T.A. Bonasera, M.J. Fusselman, D.D. Detert, P.D. Cutler, J.A. Katzenellenbogen, M.J. Welch, Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays, J. Nucl. Med. 36 (1995) 1766-1774.
133. 18F]-Fluoro-17β-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy, Clin. Cancer Res. 2 (1996) 933-939.
134. F.L. Flanagan, F. Dehdashti, J.E. Mortimer, B.A. Siegel, S.D. Jonson, M.J. Welch, PET assessment of response to tamoxifen therapy in patients with metastatic breast cancer, J. Nucl. Med. 37 (1996) 99.
135. J.A. Endicott, V. Ling, The biochemistry of P-glycoprotein mediated multidrug resistance, Annu. Rev. Biochem. 58 (1989) 137-171.
136. I.B.E. Roninson, Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells, Plenum Press, New York, 1991.
137. M.M. Gottesman, I. Pastan, Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu. Rev. Biochem. 62 (1993) 385-427.
138. S.P.C. Cole, G. Bhardwaj, G.H. Gerlach, J.E. Mackie, C.E. Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M.V. Duncan, R.G. Deelay, Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line, Science 258 (1992) 1650-1654.
139. C.J. Chen, J.E. Chin, K. Ueda, D.P. Clark, I. Pastan, M.M. Gottesman, I.B. Roninson, Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells, Cell 47 (1986) 381-389.
140. P. Gros, J. Croop, I. Roninson, A. Varshavsky, D.E. Housman, Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells, Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 337-341.
141. T.P. Miller, T.M. Grogan, W.S. Dalton, C.M. Spier, R.J. Scheper, S.E. Salmon, P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil, J. Clin. Oncol. 9 (1991) 17-24.
142. J.M. Ford, W.N. Hait, Pharmacology of drugs that alter multidrug resistance in cancer, Pharmacol. Rev. 42 (1990) 155-199.
143. A.T. Fojo, K. Ueda, D.J. Slamon, D.G. Poplack, M.M. Gottesman, I. Paston, Expression of a multidrug-resistance gene in human tumors and tissues, Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 265-269.
144. D.D. Ross, B.W. Thompson, J.V. Ordonez, C.C. Joneckis, Improvement of flowcytometric detection of multidrug-resistant cells by cell-volume normalization of intracellular daunorubicin content, Cytometry 10 (1989) 185-191.
145. T.J. Lampidis, C. Castello, A. del Giglio, B.C. Pressman, P. Viallet, K.W. Trevorrow, G.K. Valet, H. Tapiero, N. Savaraj, Relevance of the chemical charge of rhodamine dyes to multiple drug resistance, Biochem. Pharmacol. 38 (1989) 4267-4271.
146. W.S. Dalton, T.M. Grogan, J.A. Rybski, R.J. Scheper, L. Richter, J. Kailey, H.J. Broxterman, H.M. Pinedo, S.E. Salmon, Immunohistochemical detection and quantification of P-glycoprctein in mutiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation, Blood 73 (1989) 747-752.
147. H. Chan, P. Thorner, G. Haddad, V. Ling, Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood, J. Clin. Oncol. 8 (1990) 689-704.
148. P. Van der Valk, C.K. van Kalken, H. Ketelaars, H.J. Boxterman, G. Sheffer, C.M. Kuiper, T. Tsuruo, J. Lankelma, C.J. Meijer, H. Pinedo, R. Scheper, Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues, Annal. Oncol. 1 (1990) 56-64.
149. D. Kessel, W.T. Beck, T. Kukuruga, V. Schulz, Characterization of multidrug resistance by fluorescent dyes, Cancer Res. 51 (1991) 4665-4670.
150. K.E. Noonan, C. Beck, T.A. Holzmayer, J.E. Chin, J.S. Wunder, I.L. Andrulis, A.F. Gazdar, C.L. Willman, B. Griffith, D. Von Hoff, Quantitative analysis of MDRa (multidrug resistance) gene expression in human tumors by polymerase chain reaction, Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 7160-7164.
151. A.G. Jones, M.J. Abrams, A. Davison, J.W. Brodack, A.K. Toothaker, S.J. Adeistein, A.I. Kassis, Biological studies of a new class of technetium complexes: the hexakis(alkylisonitrile)technetium(I) cations, Int. J. Nucl. Med. Biol. 11 (1984) 225-234.
152. D. Piwnica-Worms, M.L. Claiu, M. Budding, J.F. Kronauge, R.A. Kramer, J.M. Croop, Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex, Cancer Res. 53 (1993) 977-984.
153. D. Piwnica-Worms, V.V. Rao, J.F. Kronauge, J.M. Croop, Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation, Biochemistry 34 (1995) 12210-12220.
154. 201Tl-thallous chloride in tumour cells: role of P-glycoprotein, Quart. J. Nucl. Med. 39 (1995) 122-1228.
155. M.D. Cordobes, A. Starzec, L. Delmon-Moingeon, C. Blanchot, J.C. Kouyoumdjian, G. Prevost, M. Caglar, J.L. Moretti, Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: Correlation with mdr gene expression, J. Nucl. Med. 37 (1996) 286-289.
156. I. Bosch, C.L. Crankshaw, D. Piwnica-Worms, J.M. Croop, Characterization of functional assays of multidrug resistance P-glycoprotein transport activity, Leukemia 11 (1997) 1131-1137.
157. S. Del-Vecchio, A. Ciarmiello, M.I. Potena, M.V. Carriero, C. Mainolfi, G. Botti, R. Thomas, M. Cerra, G. D'Aiuto, T. Tsuruo, M. Salvatore, In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients, Eur. J. Nucl. Med. 24 (1997) 150-159.
158. G.D. Luker, P.M. Fracasso, J. Dobkin, D. Piwnica-Worms, Modulation of the multidrug resistance P-glycoprotein: Detection with technetium-99m-sestamibi in vivo, J. Nucl. Med. 38 (1997) 369-372.
159. J.E. Moulder, S. Rockwell, Tumor hypoxia: its impact on cancer therapy, Br. J. Radiol. 26 (1987) 638-648.
160. S. Rockwell, S.R. Keyes, A.C. Sartorelli, Preclinical studies of porfiromycin as an adjunct to radiotherapy, Radiat. Res. 116 (1988) 100-113.
161. S. Rockwell, Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro, Int. J. Cancer 38 (1986) 229-235.
162. C.N. Coleman, Hypoxia in tumors: A paradigm for the approach to biochemical and physiological heterogeneity, J. Natl. Cancer Inst. 80 (1988) 310-317.
163. L.J. Peters, H.R. Withers, H.D. Thames, G.H. Fletcher, Keynote address - the problem: Tumor radioresistance in clinical radiotherapy, Int. J. Radiat. Oncol. Biol. Phys. 8 (1982) 101-108.
164. W.L. Rumsey, B. Patel, K. Linder, Effect of graded hypoxia in retention of technetium-99m-nitroheterocycle in perfused rat hearts, J. Nucl. Med. 36 (1995) 632-636.
165. G.J.R. Cook, S. Houston, S.F. Barrington, I. Fogelman, Technetium-99m-labeled HL91-to identify tumor hypoxia: Correlation with fluorine-18-FDG, J. Nucl. Med. 39 (1998) 99-103.
166. C.J. Mathias, M.J. Welch, M.R. Kilbourn, P.A. Jerabek, T.B. Patrick, M.E. Raichle, K.A. Krohn, J.S. Rasey, D.W. Shaw, Radiolabeled hypoxic cell sensitizers: Tracers for assessment of ischemia, Life Sci. 41 (1987) 199-206.
167. 3H] misonidazole in cerebral ischemia, Stroke 18 (1987) 168-176.
168. G.V. Martin, J.H. Caldwell, M.M. Graham, J.R. Grierson, K. Kroll, M.J. Cowan, T.K. Lewellen, J.S. Rasey, J.J. Casciari, K.A. Krohn, Non-invasive detection of hypoxic myocardium using flourine-18-fluoromisonidazole and Positron Emission Tomography, J. Nucl. Med. 33 (1992) 2202-2208.
169. M.E. Shelton, C. Dence, D.-R. Hwang, M.J. Welch, Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium, J. Nucl. Med. 30 (1989) 351-358.
170. W.J. Koh, K.S. Bergman, J.S. Rasev et al, Evaluation of oxygenation status during fractionated radiotherapy in human non-small cell lung cancers using [F-18]fluoromisonidazole and Positron Emission Tomography, Int. J. Radiat. Oncol. Biol. Phys. 33 (1995) 391-398.
171. A. Nunn, K. Linder, H.W. Strauss, Nitroimidazoles and imaging hypoxia, Eur. J. Nucl. Med. 22 (1995) 265-280.
172. K.E. Linder, Y.W. Chan, J.E. Cyr, D.P. Nowotnik, W.C. Eckelman, A.D. Nunn, Synthesis, characterization, and in vitro evaluation of nitroimidazole-BATO complexes: new technetium compounds designed for imaging hypoxic tissue, Bioconjugate Chem. 4 (1993) 326-333.
173. C.K. Ng, A.J. Sinusas, B.L. Zaret, R. Soufer, Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia, Circulation 92 (1995) 1261-1268.
174. W.L. Rumsey, J.E. Cyr, N. Raju, R.K. Narra, A novel [99m]technetium-labeled nitroheterocycle capable of identification of hypoxia in heart, Biochem. Biophys. Res. Commun. 193 (1993) 1239-1246.
175. 99mTc-labeled nitroimidazole (BMS-181321), after regional ischemia and reperfusion, Circulation 92 (1995) 1246-1253.
176. W.L. Rumsey, B. Patel, K.E. Linder, Effect of graded hypoxia on retention of technetium-99m-nitroheterocycle in perfused rat heart, J. Nucl. Med. 36 (1995) 632-636.
177. R.D. Okada, K.N. Nguyen, M. Lauinger, L.L. Allton, G.R. Johnson, Technetium-99m-Q12 kinetics in perfused rat myocardium: effects of hypoxia and low flow, Am. Heart. J. 132 (1996) 108-115.
178. J.R. Ballinger, J.W. Kee, A.M. Rauth, In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS-181321) as a marker of tumor hypoxia, J. Nucl. Med. 37 (1996) 1023-1031.
179. K.E. Linder, Y.W. Chan, J.E. Cyr, M.F. Malley, D.P. Nowotnik, A.D. Nunn, TcO(PnAO-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction, J. Med. Chem. 37 (1994) 9-17.
180. P. Wedeking, F. Yost, M. Vven, B. Patel, S. Eaton, V. Romero, K.E. Lindner, W. Rumsey, A.D. Nunn, Comparison of the biological activity of the isomers of the Tc-99m-Nitroimidazole complex BMS-194796, J. Nucl. Med. 36 (1995) 17.
181. C.M. Archer, B. Edwards, J.D. Kelly, A.C. King, J.F. Burke, A.L.M. Riley, Technetium labelled agents for imaging hypoxia in vivo, in: M. Nicolini, G. Bandoli. U. Mazzi (Eds.), Technetium and Rhenium in Chemistry and Nuclear Medicine 4, SG Editoriali, Padova, Italy, 1995.
182. R.D. Okada, G. Johnson, K.N. Nguyen, B. Edwards, C.M. Archer, J.D. Kelly, Circulation 8S (1997) 1892-1899.
183. G.J.R. Cook, S. Houston, S.F. Barrington, I. Fogelman, Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG, J. Nucl. Med. 39 (1998) 99-103.
184. Y. Fujibayashi, K. Matsumoto, Y. Yonekura, J. Konishi, A. Yokoyama, A new zinc-62/copper-62 generator as a copper-62 source for PET radiopharmaceuticals, J. Nucl. Med. 30 (1989) 1838-1842.
185. Y. Fujibayashi, H. Taniuchi, N. Tajima, Y. Yonekura, J. Konishi, A. Yokoyama, New non-nitroimidazole hypoxia imaging agents, Cu-62-dithiosemicarbazone complexes with low redox potential, J. Nucl. Med. 36 (1995) 49.
186. J.L.J. Dearling, J.S. Lewis, G.E.D. Mullen, M.T. Rae, J. Zweit, P.J. Blower, Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro, Eur. J. Nucl. Med. 25 (1998) 788-792.
187. Y. Fujibayashi, C.S. Cutler, C.J. Anderson, D.W. McCarthy, L.A. Jones, T. Sharp, Y. Yonekura, M.J. Welch, Comparative imaging studies of Cu-ATSM a hypoxia imaging agent and C-11-acetate in an acute myocardial infarction model: ex vivo imaging in rats, Nucl. Med. Biol. (in press).
188. 64Cu-ATSM): in vitro and in vivo in a hypoxic tumor model, J. Nucl. Med. (in press).
189. Y. Fujibayashi, H. Taniuchi, Y. Yonekura, H. Ohtani, J. Konishi, A. Yokoyama, Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential, J. Nucl. Med. 38 (1997) 1115-1160.
190. 4-methylthiosemicarbazone) (Cu-PTSM), a metal complex with selective NADH-dependent reduction by complex 1 in brain mitochondria: A potential radiopharmaceutical for mitochondria-functional imaging with positron emission tomography, Biol. Pharm. Bull. 18 (1995) 1126-1129.
191. C.M. Lederer, V.S. Shirley (Eds.), Table of Isotopes, John Wiley and Sons, Inc., 1978.
192. C. Loc'h, B. Mazièré, D. Comar, A new generator for ionic gallium-68, J. Nucl. Med. 21 (1979) 171-173.